{"schema_version":"secwatch.filing_event.v1","accession":"0000920148-23-000078","form_type":"8-K","ticker":"LH","cik":"0000920148","company_name":"LABCORP HOLDINGS INC.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.401452+00:00","generated_at":"2026-06-09T09:29:24.650372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Labcorp Q3 revenue up 6.6% to $3.06B; adjusted EPS $3.38 vs $4.01 YoY; narrows full-year guidance","bullets":["Q3 revenue $3.06B (+6.6% YoY); Base Business revenue grew 14.0% YoY, partially offset by lower COVID-19 testing.","GAAP diluted EPS $2.11 vs $3.06 YoY; adjusted EPS $3.38 vs $4.01 YoY.","Updated FY2023 guidance: adjusted EPS $13.25-$13.75 (midpoint unchanged), FCF $0.85-$0.95B excluding spin items.","Signed multiple hospital lab agreements including Tufts Medicine, Providence Health, Legacy Health, and Baystate Health.","Launched ATN Profile, a blood-based test combining three biomarkers to aid Alzheimer's diagnosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000920148-23-000078","json":"https://secwatch.observer/filing/0000920148-23-000078.json","markdown":"https://secwatch.observer/filing/0000920148-23-000078.md","text":"https://secwatch.observer/filing/0000920148-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000078/0000920148-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000078/lh-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:29:24.650372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da5c0efdf510b8afbafc4c0ddb5ad9bf938572cb","claim":"LABCORP HOLDINGS INC. reported the third quarter ended September 30, 2023 results: revenue $3.06 billion, net income $183.6 million, EPS $2.11. Guidance reaffirmed.","evidence_excerpt":"Guidance • Third quarter revenue grew 6.6% versus last year as the Base Business grew 14.0%. Results from Continuing Operations for third quarter versus last year: ◦ Revenue: $3.06 billion versus $2.87 billion ◦ Diluted EPS: $2.11 versus $3.06 ◦ Adjusted EPS: $3.38 versus $4.01 ◦ Free Cash Flow: $170.6 million versus $170.2 million • Full-Year 2023 Guidance from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/920148/000092014823000078/0000920148-23-000078-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$3.06 billion"},{"label":"Net income","value":"$183.6 million"},{"label":"EPS","value":"$2.11"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}